Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.
[Oncotelic Therapeutics, Inc.]
7992332
DDDDDDDD
items
1
apa
0
default
asc
1
169592
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
